GR3035776T3 - Phosphonate nucleotide compounds - Google Patents

Phosphonate nucleotide compounds

Info

Publication number
GR3035776T3
GR3035776T3 GR20010400489T GR20010400489T GR3035776T3 GR 3035776 T3 GR3035776 T3 GR 3035776T3 GR 20010400489 T GR20010400489 T GR 20010400489T GR 20010400489 T GR20010400489 T GR 20010400489T GR 3035776 T3 GR3035776 T3 GR 3035776T3
Authority
GR
Greece
Prior art keywords
halogen
alkyl
substituted
phosphonate nucleotide
alkoxy
Prior art date
Application number
GR20010400489T
Other languages
English (en)
Inventor
Masaru Ubasawa
Kouichi Sekiya
Hideaki Takashima
Naoko Ueda
Satoshi Yuasa
Naohiro Kamiya
Original Assignee
Mitsubishi Chem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chem Corp filed Critical Mitsubishi Chem Corp
Publication of GR3035776T3 publication Critical patent/GR3035776T3/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
GR20010400489T 1996-01-18 2001-04-23 Phosphonate nucleotide compounds GR3035776T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP648096 1996-01-18

Publications (1)

Publication Number Publication Date
GR3035776T3 true GR3035776T3 (en) 2001-07-31

Family

ID=11639647

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010400489T GR3035776T3 (en) 1996-01-18 2001-04-23 Phosphonate nucleotide compounds

Country Status (12)

Country Link
US (1) US5840716A (el)
EP (1) EP0785208B1 (el)
KR (1) KR100366727B1 (el)
CN (2) CN1088712C (el)
AT (1) ATE199907T1 (el)
CA (1) CA2195262C (el)
DE (1) DE69704286T2 (el)
DK (1) DK0785208T3 (el)
ES (1) ES2155219T3 (el)
GR (1) GR3035776T3 (el)
PT (1) PT785208E (el)
TW (1) TW369536B (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0632048B1 (en) * 1993-06-29 2001-03-21 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
KR20000029952A (ko) * 1996-08-13 2000-05-25 미우라 아끼라 포스포네이트뉴클레오티드화합물
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6767900B2 (en) 2000-02-29 2004-07-27 Mitsubishi Pharma Corporation Phosphonate nucleotide compound
WO2003028737A1 (en) * 2001-08-30 2003-04-10 Mitsubishi Pharma Corporation Anti-viral agents and in-vitro method for the identification of candidates able to inhibit binding of polymerase to epsilon
US20040023928A1 (en) * 2001-10-31 2004-02-05 Colacino Joseph Matthew Phosphonate nucleotide and thiadiazole compounds for the treatment of smallpox
WO2003050129A1 (en) * 2001-12-07 2003-06-19 Eli Lilly And Company Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
WO2003051881A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
TW200410972A (en) * 2002-09-13 2004-07-01 Mitsubishi Pharma Corp Crystal of 2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl)ester
TW200416034A (en) * 2002-11-15 2004-09-01 Mitsubishi Pharma Corp Medicinal composition
WO2004046157A1 (ja) * 2002-11-15 2004-06-03 Mitsubishi Pharma Corporation 2−[ビス(2,2,2-トリフルオロエチル)ホスホニルメトキシ]エチルハライドの製造方法
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
CN100475825C (zh) * 2004-03-19 2009-04-08 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物
ES2401285T3 (es) 2004-12-16 2013-04-18 The Regents Of The University Of California Fármacos con el pulmón como diana
CN1827627B (zh) * 2005-03-04 2011-05-11 北京美倍他药物研究有限公司 新的无环核苷膦酸及其酯衍生物及其医药用途
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
EP2842559A3 (en) 2005-04-08 2015-03-18 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
WO2009023299A2 (en) 2007-04-13 2009-02-19 Southern Research Institute Anti-angiogenic agents and methods of use
CN101293899B (zh) * 2007-04-28 2011-12-07 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物及其医药用途
CN102670628B (zh) * 2008-01-25 2015-11-25 奇默里克斯公司 治疗病毒感染的方法
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
BR112012002551A2 (pt) 2009-08-03 2017-06-13 Chimerix Inc composição e métodos de tratamento de infecções virais e tumores induzidos por vírus
CN102093422B (zh) 2009-12-10 2015-02-25 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物及其医药用途
EP2534150B1 (en) 2010-02-12 2017-04-05 Chimerix, Inc. Methods of treating viral infection
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc METHODS OF TREATING RETROVIRAL INFECTIONS AND ASSOCIATED DOSAGE REGIMES
CN102286026B (zh) * 2010-06-18 2014-07-02 中国人民解放军军事医学科学院毒物药物研究所 无环核苷酸类似物的盐及其晶型和药物组合物
DK3578563T3 (da) 2011-12-22 2021-05-31 Geron Corp Guanin-analoger som telomerase-substrater og påvirkere af telomerlængde
JP2015520144A (ja) 2012-05-11 2015-07-16 アクロン・モレキュールズ・アクチェンゲゼルシャフトAkron Molecules Ag 疼痛の治療のための化合物の使用
PT2970346T (pt) 2013-03-15 2018-11-09 Univ California Diésteres de fosfonato nucleosídico acíclico
CN114404427A (zh) 2014-02-13 2022-04-29 配体药物公司 前药化合物及其用途
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
HUE059067T2 (hu) 2014-09-15 2022-10-28 Univ California Nukleotid analógok
US10377782B2 (en) 2015-09-15 2019-08-13 The Regents Of The University Of California Nucleotide analogs
EP3737676B1 (en) 2018-01-09 2024-03-06 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020932D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Heterocyclic compounds
US5532225A (en) * 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
EP0618214A1 (en) * 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
EP0632048B1 (en) * 1993-06-29 2001-03-21 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives

Also Published As

Publication number Publication date
US5840716A (en) 1998-11-24
DE69704286D1 (de) 2001-04-26
KR970059181A (ko) 1997-08-12
EP0785208A1 (en) 1997-07-23
DK0785208T3 (da) 2001-04-23
CN1088712C (zh) 2002-08-07
CA2195262C (en) 2005-08-09
CN1398864A (zh) 2003-02-26
KR100366727B1 (ko) 2003-03-15
EP0785208B1 (en) 2001-03-21
ES2155219T3 (es) 2001-05-01
TW369536B (en) 1999-09-11
PT785208E (pt) 2001-06-29
ATE199907T1 (de) 2001-04-15
CA2195262A1 (en) 1997-07-19
DE69704286T2 (de) 2001-10-25
CN1164534A (zh) 1997-11-12
CN1216060C (zh) 2005-08-24

Similar Documents

Publication Publication Date Title
GR3035776T3 (en) Phosphonate nucleotide compounds
TW370450B (en) Substituted 1H-3-aryl-pyrrolidine-2,4-dione derivatives
AP2000001803A0 (en) Chemical compounds
HK1019878A1 (en) Total synthesis of antitumor acylfulvenes.
HU9502512D0 (en) Anthranilic acid derivative
ZA976705B (en) Process for the synthesis of protected esters of (S)-3,4-dihydroxybutric acid.
AU1039688A (en) 3(2h)pyridazinone, process for its preparation and antagonistic agent against srs-a containing it
HK1039316A1 (zh) 具有一氧化氮合成酶抑制作用的苯胺衍生物
ES2142773A1 (es) Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
HK1031867A1 (en) 2-phenoxyaniline derivatives
MX9701949A (es) Derivados de distamicina substituidos con bis-(2-haloetil) aminofenilo como agentes antitumorales y antivirales.
NZ304438A (en) Substituted triazole derivatives and antifungal compositions
DE69612967D1 (en) Optisch aktive thiazolidinonderivate
AU2001283125A1 (en) Compositions for defoaming aqueous compositions
TW356471B (en) Novel carbocyclic nucleoside agents useful as selective inhibitor of proinflammatory cytokines
AU3285000A (en) 22r-hydroxycholesta-8,14-diene derivatives for the inhibition of meiosis
EP0742211A4 (en) PYRIDAZINONE DERIVATIVES
IL170056A (en) Pyrazole compounds
NO972905L (no) Tienoksasinon-derivater anvendelige som antivirusmidler
AU5660598A (en) Use of aminoisothiazoles as microbicides
EP0443474A3 (en) 1-phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents
WO1999011621A3 (en) Thiourea for increasing hdl-cholesterol levels, which are useful as anti-atherosclerotic agents
TW358087B (en) Method for preparing carbamoylmethylurea derivatives
EP0936215A4 (en) PROCESS FOR THE PREPARATION OF 2-PHENYL-3-NAPHTYLPROPIONIC ACID DERIVATIVES
ES2067388A1 (es) Procedimiento para la produccion de derivados de piroglutamato de configuracion 2,4-cis

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees